Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Brain Tumor Adult

Interventions

DRUG

Hyperpolarized 13C-Pyruvate

Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.

DRUG

Gadolinium

Brain MRI performed with and without gadolinium-based contrast.

Trial Locations (1)

RECRUITING

UT Southwestern Medical Center, Dallas

All Listed Sponsors

lead

University of Texas Southwestern Medical Center

OTHER